WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 10, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

The active substance of Kavigale is sipavibart, an antiviral human IgG1 monoclonal antibody discovered by RQ Bio in partnership with The University of Oxford. Sipavibart provides passive protection ...

Posdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific ...

This is a useful study that adds new data to how different DAG pools influence cellular signaling, and dissects how the enzyme Dip2 modulates the minor lipid signaling DAG pool, which is distinct from ...

Fighting off infections when one has a chronic disease is a common problem, and during the COVID-19 pandemic that scenario ...

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a ...

Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 -- Clinical data update expected in Q2 2025 - ...

Numerous court decisions over the past decade – such as Amgen Inc. v. Sanofi from the US Supreme Court and Juno Therapeutics, Inc. et al. v.

Dubai Investment Fund (DIF), a leading global investment fund, is pleased to announce the change of its official domain name to a new address ? dif.co. This change reflects DIF's commitment to ...

Donor DNA monitoring in kidney transplant patients detects antibody-mediated rejection early, improving outcomes and ...

Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic ...